Cited by 435Parkinson's Disease Mechanisms and TreatmentsMitochondrial Function and PathologyCoenzyme Q10 studies and effects

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Low platelet mitochondrial complex I and complex II/III activity in early untreated parkinson's disease

Haas, Richard H., Nasirian, Fatemeh, Nakano, Kazutoshi, Ward, David, Pay, Mary, Hill, Robert, Shults, Clifford W.·1995·Annals of Neurology

DOI 10.1002/ana.410370604

Open this paper in CoChat — free account

Abstract

Following the discovery of inhibition of electron transport complex I by the neurotoxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP), which produces a parkinsonian syndrome in humans, monkeys, and mice, several laboratories have reported abnormalities of complex I and other electron transport complexes (ETCs) in various tissues from patients with Parkinson's disease (PD). Criticism of the significance of these findings in the etiology of PD has centered on whether drug treatments or the debilitation of the disease process itself produced the low ETC activities. We present results from a blinded study of platelet mitochondrial ETC activities in 18 early untreated PD patients and 18 age‐ and sex‐matched controls and in 13 spousal controls. Lower complex I activity in platelet mitochondria of PD patients was seen in early untreated disease and thus cannot be due to debilitation or drug therapy. Home environmental factors seem an unlikely explanation for the reduced complex I activity in PD patients but have not been excluded. Complex II/III activity was also reduced by 20% in PD compared with age‐/sex‐matched controls. The low complex I and II/III activities in platelet mitochondria appear to be related to the etiology of PD.

Integrity signals

Registry

Crossref · 10.1002/ana.410370604

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O. H., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 316,394
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Mitochondrial Complex I Deficiency in Parkinson's Disease
Schapira, A. H. V., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., & Marsden, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb02325.x · Cited by 2,283
MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE
Schapira, A. H. V., Cooper, J. A. D., Dexter, D. T., Jenner, P. G., Clark, J. B., & MARSDEN, C. D. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92366-0 · Cited by 1,757
Abnormalities of the electron transport chain in idiopathic parkinson's disease
Parker, W. D., Boyson, S. J., & Parks, J. K. (1989) · Annals of Neurology · doi:10.1002/ana.410260606 · Cited by 1,061
Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain
Mecocci, P., MacGarvey, U., Kaufman, A. E., Koontz, D., Shoffner, J. M., Wallace, D. C., & Beal, M. F. (1993) · Annals of Neurology · doi:10.1002/ana.410340416 · Cited by 757
CENTRAL CERVICAL CORD SYNDROME AFTER HEADING A FOOTBALL
Scoppetta, C., & Vaccario, M. L. (1978) · The Lancet · doi:10.1016/s0140-6736(78)92517-5 · Cited by 755
Deficiencies in Complex I subunits of the respiratory chain in Parkinson's disease
Mizuno, Y., Ohta, S., Tanaka, M., Takamiya, S., Suzuki, K., SATO, T. A., Oya, H., Ozawa, T., & Kagawa, Y. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)91141-8 · Cited by 735
Spectrophotometric Assay of Cytochrome c Oxidase
Smith, L. (1955) · Methods of biochemical analysis · doi:10.1002/9780470110188.ch13 · Cited by 506
Mitochondrial DNA Variants Observed in Alzheimer Disease and Parkinson Disease Patients
Shoffner, J. M., Brown, M. D., Torroni, A., Lott, M. T., Cabell, M. F., Mirra, S. S., Beal, M. F., Yang, C.-C., Gearing, M., Salvo, R., et al. (1993) · Genomics · doi:10.1006/geno.1993.1299 · Cited by 450

Flagged first, then by citations

Show all 47 references

Research works printed but not linked: 1

Lang AET, 1989, Quantification of neurological deficit, 289

Sorted by citations

Items 301–400 of 434

Physiology and Pathology of Neuroimmunology: Role of Inflammation in Parkinson’s Disease
Ortíz, G. G., González-Usigli, H., Pacheco-Moisés, F. P., Mireles-Ramírez, M. A., Sánchez-López, A. L., Torres-Sánchez, E. D., González-Renovato, E. D., Flores-Alvarado, L. J., Macías-Islas, M. Á., Rivero-Moragrega, P., et al. (2017) · InTech eBooks · doi:10.5772/intechopen.70377 · Cited by 13
The genetics of Parkinson's disease and parkinsonian syndromes
Bajaj, N. P. S., Shaw, C. E., Warner, T. T., & Chaudhuri, К. R. (1998) · Journal of Neurology · doi:10.1007/s004150050258 · Cited by 13
Is there a pathogenic role for mitochondria in Parkinson's disease?
Vives-Bauzá, C., de Vries, R. L. A., Tocilescu, M. A., & Przedborski, S. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70823-5 · Cited by 12
Profiling genes related to mitochondrial function in mice treated with N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Gu, G., Deutch, A. Y., Franklin, J., Levy, S., Wallace, D. C., & Zhang, J. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)01233-6 · Cited by 12
Unveiling the mechanism of platelet dysfunction in Parkinson's disease: The effect of 6-hydroxydopamine on human blood platelets
Beura, S. K., Yadav, P., Panigrahi, A. R., & Singh, S. K. (2023) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2023.105453 · Cited by 11
Trichloroethylene and Parkinson Disease
Zaheer, F., & Slevin, J. T. (2011) · Neurologic Clinics · doi:10.1016/j.ncl.2011.05.001 · Cited by 11
Differential Effects of Yeast NADH Dehydrogenase (Ndi1) Expression on Mitochondrial Function and Inclusion Formation in a Cell Culture Model of Sporadic Parkinson’s Disease
Cronin-Furman, E. N., Barber‐Singh, J., Bergquist, K. E., Yagi, T., & Trimmer, P. A. (2019) · Biomolecules · doi:10.3390/biom9040119 · Cited by 13
The redox physiology of red blood cells and platelets: implications for their interactions and potential use as systemic biomarkers
Cortese-Krott, M. M., & Shiva, S. (2019) · Current Opinion in Physiology · doi:10.1016/j.cophys.2019.04.016 · Cited by 11
Do mtDNA Mutations Participate in the Pathogenesis of Sporadic Parkinsons Disease?
Kirches, E. (2009) · Current Genomics · doi:10.2174/138920209789503879 · Cited by 11
Blood and cerebrospinal fluid markers in Parkinson's disease: current biomarker findings
Henchcliffe, C. (2014) · Current Biomarker Findings · doi:10.2147/cbf.s50424 · Cited by 11
Movement disorders and mitochondrial disease
Moustris, A., Edwards, M. J., & Bhatia, K. P. (2011) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52014-2.00010-0 · Cited by 11
Bioenergetic and oxidative effects of free 3‐nitrotyrosine in culture: selective vulnerability of dopaminergic neurons and increased sensitivity of non‐dopaminergic neurons to dopamine oxidation
Ma, T. C., Mihm, M. J., Bauer, J. A., & Hoyt, K. R. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04735.x · Cited by 11
Mitochondrial Dynamics in Neurodegenerative Diseases
Pinnell, J. R., & Tieu, K. (2017) · Advances in neurotoxicology · doi:10.1016/bs.ant.2017.07.006 · Cited by 10
Ca2+ signalling: A common language for organelles crosstalk in Parkinson's disease
Peggion, C., Barazzuol, L., Poggio, E., Calí, T., & Brini, M. (2023) · Cell Calcium · doi:10.1016/j.ceca.2023.102783 · Cited by 10
Mitochondrial therapy for Parkinson’s disease: Neuroprotective pharmaconutrition may be disease-modifying
KONES, R. J. (2010) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s12082 · Cited by 11
Stimulation of electron transport as potential novel therapy in Parkinson's disease with mitochondrial dysfunction
Vos, M. H., Verstreken, P., & Klein, C. (2015) · Biochemical Society Transactions · doi:10.1042/bst20140325 · Cited by 10
Mitochondrial Medicine
Gvozdjáková, A. (2008) · Springer eBooks · doi:10.1007/978-1-4020-6714-3_5 · Cited by 10
Unaltered cytochrome oxidase, glutamate dehydrogenase and glutaminase activities in platelets from patients with Sporadic Amyotrophic Lateral Sclerosis
Gluck, M. R., Thomas, R. G., & Sivak, M. A. (2000) · Journal of Neural Transmission · doi:10.1007/s007020070007 · Cited by 10
Is there a genetic susceptibility to idiopathic parkinsonism?
Wilhelmsen, K. C., & Wszołek, Z. K. (1995) · Parkinsonism & Related Disorders · doi:10.1016/1353-8020(95)00021-6 · Cited by 9
Mitochondrial complex I deficiency occurs in skeletal muscle of a subgroup of individuals with Parkinson’s disease
Kverneng, S. U., Stige, K. E., Berven, H., Mostafavi, S., Lundervold, K., Brischigliaro, M., Brakedal, B., Skeie, G. O., Flønes, I. H., Toker, L., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-00817-7 · Cited by 8
Metabolic Dysregulation in Parkinson’s Disease: Non-Oxidative Phosphorylation and Its Role in Brain Energy Metabolism
Pokotylo, M. M., Brüggemann, N., & Prasuhn, J. (2025) · Aging and Disease · doi:10.14336/ad.2025.0619 · Cited by 8
Parkinson's disease relevant pathological features are manifested in male Pink1/Parkin deficient rats
Lamberty, B. G., Estrella, L. D., Mattingly, J. E., Emanuel, K. M., Trease, A. J., Totusek, S., Sheldon, L., George, J. W., Almikhlafi, M. A., Farmer, T., et al. (2023) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2023.100656 · Cited by 10
Neurodegenerative Diseases: Potential Effect of Glutathione
Moustapha, A. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.92240 · Cited by 8
Pesticides and Parkinson’s Disease
Arthur, G., & Jeff, M. (2011) · InTech eBooks · doi:10.5772/16479 · Cited by 8
Mitochondria and Parkinson's Disease
Simon, D. K., Chu, C. T., & Swerdlow, R. H. (2011) · Parkinson s Disease · doi:10.4061/2011/261791 · Cited by 8
Acetyl-L-Carnitine in Parkinson’s Disease
Stefania, M., Rovito, N., Carocci, A., & Genchi, G. (2012) · InTech eBooks · doi:10.5772/19668 · Cited by 8
Parkinson's disease
Korlipara, L. V. P., & Schapira, A. H. V. (2002) · International review of neurobiology · doi:10.1016/s0074-7742(02)53011-7 · Cited by 8
Complex I superoxide anion production is necessary and sufficient for complex I inhibitor-induced dopaminergic neurodegeneration in Caenorhabditis elegans
Morton, K. S., George, A. J., & Meyer, J. N. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103538 · Cited by 7
Garcinia morella extract confers dopaminergic neuroprotection by mitigating mitochondrial dysfunctions and inflammation in mouse model of Parkinson’s disease
Dutta, A., Phukan, B. C., Roy, R., Mazumder, M. K., Paul, R. K., Choudhury, A., Kumar, D., Bhattacharya, P., Nath, J., Kumar, S., et al. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-022-01001-9 · Cited by 7
Parkinson's Disease
Rango, M. (2015) · International review of neurobiology · doi:10.1016/bs.irn.2015.05.007 · Cited by 7
Mitochondria in the etiology of Parkinson's disease
Schapira, A. H. V. (2007) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)83022-3 · Cited by 7
What's wrong with mitochondria in Parkinson's disease?
Greenamyre, J. T. (2018) · Movement Disorders · doi:10.1002/mds.98 · Cited by 7
The heat shock protein DNAJB2 as a novel biomarker for essential thrombocythemia diagnosis associated with immune infiltration
Chen, H., Lin, C., Xue, H., Chen, C., & Yang, M. (2023) · Thrombosis Research · doi:10.1016/j.thromres.2023.01.029 · Cited by 6
MicroRNA-593-5p contributes to cell death following exposure to 1-methyl-4-phenylpyridinium by targeting PTEN-induced putative kinase 1
Yoo, M., Choi, D. C., Murphy, A., Ahsan, A. M., & Junn, E. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104709 · Cited by 6
A Role for the Vesicular Monoamine Transporter (VMAT2) in Parkinson’s Disease
German, D. C., & Sonsalla, P. K. (2002) · Advances in behavioral biology · doi:10.1007/978-1-4615-0179-4_13 · Cited by 6
The Use of Biomarkers for Prediction and Prevention of Alzheimer’s and Parkinson’s Diseases
Mandel, S. A., & Korczyn, A. D. (2012) · Advances in predictive, preventive and personalised medicine · doi:10.1007/978-94-007-5866-7_6 · Cited by 6
Oxidative Stress in Parkinson’s Disease: Role in Neurodegeneration and Targets for Therapeutics
Banerjee, R., Kaidery, N. A., & Thomas, B. (2015) · ACS symposium series · doi:10.1021/bk-2015-1200.ch005 · Cited by 7
Toxin-Mediated Complex I Inhibition and Parkinson’s Disease
Miranda, B. R. D., Houten, B. V., & Sanders, L. H. (2016) · Springer eBooks · doi:10.1007/978-3-319-42139-1_6 · Cited by 6
Redox Enzymes
Dykens, J. A. (2007) · Elsevier eBooks · doi:10.1016/b0-08-045044-x/00071-7 · Cited by 6
Epidemiology of Parkinson's Disease: The Rotterdam Study
de Rijk, M. (1997) · RePub (Erasmus University Rotterdam) · Cited by 6
The dysregulated Pink1- Drosophila mitochondrial proteome is partially corrected with exercise
Ebanks, B., Ingram, T. L., Katyal, G., Ingram, J. R., Moisoi, N., & Chakrabarti, L. (2021) · Aging · doi:10.18632/aging.203128 · Cited by 6
Role of Mitochondria in Neurodegenerative Diseases: The Dark Side of the “Energy Factory”
Correia, S. C., & Moreira, P. I. (2018) · Springer eBooks · doi:10.1007/978-3-319-73344-9_11 · Cited by 5
Mitochondrial Proteins in the Development of Parkinson’s Disease
Zilocchi, M., Fasano, M., & Alberio, T. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-8367-0_2 · Cited by 5
Statininduziertes Parkinson-Syndrom
Müller, T. (2003) · Der Nervenarzt · doi:10.1007/s00115-003-1528-z · Cited by 5
Mitotherapy in Alzheimer’s and Parkinson’s diseases: A systematic review of preclinical studies
Modiri, A., Hosseini, L., Abolhasanpour, N., Azizi, H., & Sadeh, R. N. (2025) · BMC Neurology · doi:10.1186/s12883-025-04241-1 · Cited by 4
The Energy Crisis in Parkinson’s Disease: A Therapeutic Target
Abou-Hamdan, M., Cornille, E., Khrestchatisky, M., de, M. B. A. B., & Gharib, B. (2011) · InTech eBooks · doi:10.5772/17369 · Cited by 5
Mitochondrial respiratory chain enzyme activities, mtDNA variants and gene expression levels in idiopathic parkinson’s disease
Ercan, A., Kulaksiz-Erkmen, G., Dalmızrak, Ö., Müftüoğlu, M., Öğüş, İ. H., Cavdar, L. Y., İnan, L. E., & Özer, N. K. (2009) · Turkish Journal of Biochemistry · Cited by 4
Mitochondrial dysfunction in Parkinson’s disease: a possible target for neuroprotection
Gleave, J. A., Perri, P. D., & Nash, J. E. (2014) · Frontiers in Biology · doi:10.1007/s11515-014-1337-8 · Cited by 5
The Role of Pesticide-Induced Aldehyde Dehydrogenase Inhibition in the Pathogenesis of Parkinson’s Disease
Fitzmaurice, A. G. (2012) · CaltechTHESIS (California Institute of Technology) · doi:10.7907/fdag-hh02 · Cited by 4
A mitochondrial blood-based patient stratification candidate biomarker for Parkinson’s diseasePreprint
Qi, R., Sammler, E. M., González-Hunt, C. P., Pena, N., Rouanet, J. P., Goodson, S. D., Fuzatti, M., Blandini, F., Erickson, K. I., Weinstein, A. M., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.07.479309 · Cited by 4
Platelet Bioenergetics and Associations With Delirium and Coma in Patients With Sepsis
Onyemekwu, C. A., Prendergast, N. T., Potter, K. M., Toney, N. A., Nouraie, M. S., Shiva, S., & Girard, T. D. (2024) · CHEST Critical Care · doi:10.1016/j.chstcc.2024.100076 · Cited by 3
Mitochondrial respiration defects in lymphoblast cell lines from patients with Dravet syndrome
Figueroa, A. G., Fulton, R. E., Banerji, R., Knupp, K. G., & Patel, M. N. (2025) · Epilepsia · doi:10.1111/epi.18382 · Cited by 3
Electron Transport Chain
Aerts, L., & Morais, V. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803783-6.00002-x · Cited by 3
Cerebrospinal Fluid (CSF) Concentration of Coenzyme Q10 in Clinical Practice, A Breaking News Finding in Humans
Naini, A., & Singh, R. B. (2009) · The Open Nutraceuticals Journal · doi:10.2174/1876396000902010013 · Cited by 3
Insights into various dysfunctions in Parkinson’s disease: a survey
Dhar, S., Singh, J., & Singh, P. (2016) · CSI Transactions on ICT · doi:10.1007/s40012-016-0127-7 · Cited by 3
Colonic Oxidative and Mitochondrial Function in Parkinson’s Disease and Idiopathic REM Sleep Behavior Disorder
Morén, C., González‐Casacuberta, I., Navarro‐Otano, J., Juárez‐Flores, D. L., Vilas, D., Garrabou, G., Milisenda, J. C., Pont‐Sunyer, C., Catalán‐García, M., Guitart‐Mampel, M., et al. (2017) · Parkinson s Disease · doi:10.1155/2017/9816095 · Cited by 4
Disruption of intracellular signaling
Kanthasamy, A. G., Luo, J. D., Rokad, D., & Charli, A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813602-7.00007-7 · Cited by 3
Parkinson's Disease: Mechanisms of Neuronal Death
Kolesnikova, E. E., & Serebrovskaya, T. V. (2003) · Neurophysiology · doi:10.1023/a:1023902507735 · Cited by 3
Agrochemicals-Induced Dopaminergic Neurotoxicity: Role of Mitochondria-Mediated Oxidative Stress and Protein Clearance Mechanisms
Singh, N., Lawana, V., Krishnan, N., Kanuri, S. H., Jin, H., Anantharam, V., Kanthasamy, A. G., & Kanthasamy, A. (2015) · Current topics in neurotoxicity · doi:10.1007/978-3-319-13939-5_10 · Cited by 3
Heme metabolism, mitochondria, and complex I in neuropsychiatric disorders
Ifhar, L. S., & Ben‐Shachar, D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814037-6.00008-2 · Cited by 3
Molecular Etiology of Parkinson Disease: Recent Progress
Shastry, B. S. (2000) · The Neuroscientist · doi:10.1177/107385840000600406 · Cited by 3
Heterocyclic aromatic amines (HAAs) target mitochondrial physiologyPreprint
Sammi, S. R., Syeda, T., Foguth, R. M., & Cannon, J. R. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.17.484822 · Cited by 3
Mitochondrial Function and Neurodegenerative Diseases
Wilkins, H. M., Weidling, I., Koppel, S., Wang, X., von Schulze, A., & Swerdlow, R. H. (2018) · The Molecular and Cellular Basis of Neurodegenerative Diseases · doi:10.1016/b978-0-12-811304-2.00013-4 · Cited by 2
Mitochondrial dysfunction in diabetes mellitus
Anderson, C. M. (1999) · Drug Development Research · doi:10.1002/(sici)1098-2299(199901)46:1 · Cited by 18
A Perspective on the Role of Mitochondrial Biomolecular Condensates (mtBCs) in Neurodegenerative Diseases and Evolutionary Links to Bacterial BCs
Calcagnile, M., Alifano, P., Damiano, F., Pontieri, P., & Giudice, L. D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178216 · Cited by 2
MODELING OF PARKINSON’S DISEASE USING ENVIRONMENTAL NEUROTOXINS (REVIEW)
Игоревна, К. О., Федорова, Т. Н., & Orlova, V. S. (2019) · Toxicological Review · doi:10.36946/0869-7922-2019-2-9-15 · Cited by 2
Biomarkers of Parkinson’s disease
Jin, H., Kanthasamy, A., Anantharam, V., & Kanthasamy, A. G. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-404630-6.00049-x · Cited by 2
Complex I Assay in Mitochondrial Preparations from CNS
Diwakar, L., Ray, A., & Ravindranath, V. (2008) · Current Protocols in Toxicology · doi:10.1002/0471140856.tx1710s38 · Cited by 2
A study of combination treatment with nacom (levodopa + carbodope) and citicoline in the model of Parkinson disease in rats
Кашкин, В. А., Шекунова, Е. В., Макарова, М. Н., & Makarov, V. G. (2017) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro20171177159-63 · Cited by 2
Mitochondrial Approaches to Neuroprotection
Beal, M. F. (2002) · Handbook of experimental pharmacology · doi:10.1007/978-3-662-06274-6_4 · Cited by 2
Pink1/Parkin deficiency alters circulating lymphocyte populations and increases platelet-T cell aggregates in rats
Manganaro, J. E., Emanuel, K. M., Lamberty, B. G., George, J. W., & Stauch, K. L. (2024) · Scientific Reports · doi:10.1038/s41598-024-74775-w · Cited by 2
Platelets mitochondrial function depends on CoQ10 concentration in winter, not in spring season
Gvozdjáková, A., Kucharská, J., Sumbalová, Z., Nemec, M., Chládeková, A., Vančová, O., Rausová, Z., Kubalová, M., & Kuzmiaková, V. M. Z. (2019) · General Physiology and Biophysics · doi:10.4149/gpb_2019012 · Cited by 2
Characterization of FBXO7 (PARK15) knockout mice modeling Parkinsonian-Pyramidal Syndrome
Vingill, S. (2017) · doi:10.53846/goediss-6254 · Cited by 1
Importance of Mitochondrial Quality Control in Parkinson’s Disease: The Potential Interplay of Mitochondrial Unfolded Protein Response and Mitophagy
Lee, Y. M., Hu, D., & Liou, Y. (2021) · Springer eBooks · doi:10.1007/978-981-16-0522-2_5 · Cited by 1
Platelet mitochondrial complex I and IV activities are not reliable stratification biomarkers in Parkinson's disease
Kverneng, S. U., Mostafavi, S., Mikhaleva, Y., Johanson, G. A. S., Berven, H., Lundervold, K., Skeie, G. O., Sheard, E. V., Søgnen, M., Geijerstam, S. A. A., et al. (2025) · Journal of Parkinson s Disease · doi:10.1177/1877718x251365253 · Cited by 1
Mitochondrial Fission-Fusion and Parkinson’s Disease: A Dynamic Question of Compensatory Networks
Chu, C. T., & Berman, S. (2011) · Springer eBooks · doi:10.1007/978-94-007-1291-1_7 · Cited by 1
Complex I Inhibition, Rotenone and Parkinson's Disease
Betarbet, R. S., & Greenamyre, J. T. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-374028-1.00014-2 · Cited by 1
Mitochondrial Dysfunction and Neurodegenerative Diseases
Lin, M., & Beal, M. F. (1998) · Springer eBooks · doi:10.1007/978-3-662-12509-0_13 · Cited by 1
Mitochondrial Therapeutic Approaches in Parkinson’s Disease
Esteves, A. R., Silva, D. F., G-Fernandes, M., Gomes, R., & Cardoso, S. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-42139-1_9 · Cited by 1
Parkinson’s Disease in Humans and in Nonhuman Primate Aging and Neurotoxin Models
Metzger, J. M., Jones, C. A., & Emborg, M. E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811353-0.00046-4 · Cited by 1
Rotenone Rat and Other Neurotoxin Models of Parkinson Disease
Sherer, T., Betarbet, R. S., & Greenamyre, J. T. (2005) · Elsevier eBooks · doi:10.1016/b978-012088382-0/50013-x · Cited by 1
Rotenone Model for Parkinson’s Disease
Betarbet, R. S., & Greenamyre, J. T. (2007) · CRC Press eBooks · doi:10.3109/9781420019223-25 · Cited by 1
Translational bioenergetics: blood cells based laboratory diagnostics
Черепнев, Г. В., Novozhilova, A. A., Ягудина, Л. А., Antzilevich, L. M., & Prokopiev, Y. V. (2022) · Laboratory Service · doi:10.17116/labs20221103134 · Cited by 1
Mitochondria and Parkinson’s Disease
Swerdlow, R. H. (2001) · Humana Press eBooks · doi:10.1007/978-1-59259-006-3_10 · Cited by 1
Prediction and targeted prevention of Parkinson's and Alzheimer's diseases
Mandel, S. A., Halperin, I. J. Y., Korczyn, A. D., & Morelli, M. (2009) · Cited by 1
Dopamine Oxidation and Parkinson’s Disease
Barrett, C. W., Bucher, M. L., & Hastings, T. G. (2017) · Royal Society of Chemistry eBooks · doi:10.1039/9781782622888-00116 · Cited by 1
Potential Therapies for Mitochondrial Dysfunction
Henchcliffe, C., & Beal, M. F. (2011) · Springer eBooks · doi:10.1007/978-0-85729-701-3_13 · Cited by 1
Progress and development in Parkinson disease therapy
Bjarkam, C. R., & Sørensen, J. C. H. (2007) · Springer eBooks · doi:10.1007/1-4020-5058-5_3 · Cited by 1
Cellular function and toxicity of the Parkinson’s disease-related genes α-synuclein and catp-6 in C. elegans
Wender, N. (2013) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-3753 · Cited by 1
Neuropathological characterization of FL-PGC-1α-deficient mice – implications for mitochondrial encephalopathy
Szalárdy, L. (2016) · SZTE Repository of Dissertations (University of Szeged) · doi:10.14232/phd.3120 · Cited by 1
Mitochondrial Dysfunction and Protein Aggregation in the Cybrid Cell Model of Parkinson's Disease
Cronin-Furman, E. N. (2013) · doi:10.18130/v3dz3t · Cited by 1
Caractérisation des activités cytoprotectrices de molécules utilisées dans le traitement de la sclérose en plaques (diméthyle fumarate, monométhyle fumarate, biotine) sur des oligodendrocytes 158N : impact sur le stress oxydant, le statut mitochondrial, le statut lipidique, l’apoptose et l’autophagie
Sghaier, R. (2019) · theses.fr (ABES) · doi:10.70675/5d9752b6zd8dcz4044z9137zad307bac6dbd · Cited by 1
Increased activity of surviving locus ceruleus neurons in Alzheimer's disease
Moser (1999) · Pure Amsterdam UMC · doi:10.1002/1531-8249(199901)45:1
Self-citation
The Control of Ageing and Mitochondria
Lestienne, P. P., & Véziers, J. (1999) · Springer eBooks · doi:10.1007/978-3-642-59884-5_17
Disorders of mitochondrial DNA polymerase: a clinical, biochemical and structural study
Palin, E. (2013) · Työväentutkimus Vuosikirja
The proteomic approach to investigate Parkinson's desease: pathogenetic mechanisms and biomarkers discovery.
Alberio, T. (2010) · IrInSubria (University of Insubria)
Mechanisms of dopaminergic neurotoxin-induced blood-brain barrier disruption
Larsen, N. J. (2007) · D-Scholarship@Pitt (University of Pittsburgh)
Current and potential treatments of Parkinson's disease
Shults, C. W. (2005) · Cambridge University Press eBooks · doi:10.1017/cbo9780511544873.043
Self-citation
Microdevices for Isolating Single Axons for the Study of Axonal Transport in Dopaminergic Neurons
Lu, X. (2013) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7ft8j1n
Efeito de antioxidantes naturais em modelos parkinsonianos de Saccharomyces cerevisiae.
Zampol, M. A. (2013) · doi:10.11606/d.42.2013.tde-24052014-122243

Authors: Haas, R. H., Nasirian, F., Nakano, K., Ward, D., Pay, M., Hill, R., & Shults, C. W.
Affiliations: University of California San Diego (US)
Veterans Health Administration (US)
ORCID: Haas, Richard H.
Nakano, Kazutoshi
Ward, David
Hill, Robert
Venue: Annals of Neurology
Publisher: Wiley
Published: 1995-06
Volume: 37
Issue: 6
Pages: 714-722
ISSN: 0364-5134 (ISSN-L)
1531-8249
DOI: 10.1002/ana.410370604
OpenAlex: W2112777355
Cited by: 435
References: 47
Citations by year: 2026: 5 · 2025: 9 · 2024: 6 · 2023: 9 · 2022: 14 · 2021: 14 · 2020: 19 · 2019: 23 · 2018: 13 · 2017: 18 · 2016: 8 · 2015: 22 · 2014: 9 · 2013: 15 · 2012: 11
FWCI: 7.62
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 3417 d)
Locations: Annals of Neurology (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (5r01ns029504-03)
National Institute of Neurological Disorders and Stroke (R01 NS29504)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
Keywords: Parkinson's disease, platelet mitochondria, mitochondrial electron transport chain, complex I, MPTP, etiology, mitochondrial dysfunction
MeSH terms: Adult, Aged, Blood Platelets, Citrate (si)-Synthase, Female, Humans, Male, Middle Aged, Mitochondria, Multienzyme Complexes, Oxidoreductases, Parkinson Disease, Smoking, Succinate Dehydrogenase, Electron Transport Complex III, NAD(P)H Dehydrogenase (Quinone), Electron Transport Complex II

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Low platelet mitochondrial complex I and complex II/III activity in early untreated parkinson's disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks